The role of proteinase activated receptor-2 in osteoblast behaviour in prostate cancer bone metastasis
Year: 2015
Type: dissertation
Abstract: Prostate cancer is the second leading cause of cancer deaths in men, with >80% cases developing osteogenic bone metastases. The G protein-coupled receptor, protease-activated receptor-2 (PAR2), is expressed by osteoblasts and required for normal skeletal growth and repair. Prostate cancer cells express three known PAR2 agonists, the soluble serine protease kallikrein related peptidase 4 and the membrane anchored serine proteases matriptase and transmembrane protease serine 2. This study aimed to investigate the effect of factors secreted by prostate cancer cells on PAR2 mediated osteoblast behaviour and to identify cell signalling pathways that may be responsible for these effects. The experiments described in this thesis use a cell-culture model to investigate the effect of soluble factors secreted by prostate cancer cells on primary osteoblasts and bone marrow stromal cells from wild type and PAR2-knock out (KO) mice. Primary osteoblasts or bone marrow stromal cells were treated with control media and media conditioned by human prostate cancer cell lines PC3, 22Rv1, DU145 and MDA-PCA-2b. Proliferation of osteoblasts was measured by BrdU incorporation. Effects on differentiation were investigated using assays for mineralisation, alkaline phosphatase activity, Oil Red O staining, and quantitative PCR for expression of osteoblast and adipocyte-associated genes. Further experiments were conducted to investigate cell signalling pathways mediating the effects exerted by MDA-PCa-2b conditioned medium on wild type and PAR2 KO osteoblasts. In primary osteoblast cultures, MDA-PCa-2b conditioned medium (MDA-CM) promoted proliferation independently of PAR2. However, MDA-CM promoted osteoblastic differentiation in a PAR2-dependent manner as demonstrated by significant increases in Runx2 and Col1a1 gene expression and mineralisation in wild type but not PAR2 KO cells. In cultures of PAR2 KO but not wild type osteoblasts, MDA-CM increased adipocyte number and stimulated expression of the adipocyte-associated genes Pparϒ and Lpl. Moreover, expression of Pparϒ mRNA was significantly greater in untreated PAR2 KO cultures than in wild type cultures. These observations indicate that, in the presence of PAR2, osteoblast differentiation is favoured while in PAR2 KO osteoblasts adipocyte differentiation occurs. Treatment with MDA-CM had no effect on proliferation or differentiation of either wild type or PAR2 KO bone marrow stromal cells into either the osteoblast or adipocyte lineage. However, the percentage of alkaline phosphatase and von Kossa positive colonies were significantly higher in untreated wild type cultures compared to untreated PAR2 KO cultures, while the percentage of oil red O positive colonies was greater in untreated PAR2 KO cultures compared to untreated wild type cultures. Further experiments on potential molecular mechanisms by which MDA-CM exerts its PAR2 dependent and independent effects on primary osteoblast cultures were conducted. It was demonstrated that MDA-CM contains serine protease activity and inhibition of this activity abolished the ability of MDA-CM to induce markers of osteoblast differentiation, suggesting that MDA-CM-induced osteogenic differentiation is exerted through direct activation of PAR2. MDA-CM is known to contain WNTs that activate canonical WNT signalling, however in experiments conducted to determine whether MDA-CM stimulated WNT/β-catenin signalling in primary osteoblast cultures (western blot analysis of nuclear accumulation of β-catenin), no evidence of such signalling was obtained. Regulation of gene expression in wild type and PAR2 KO osteoblasts in response to MDA-CM treatment was investigated using RNA-sequencing followed by analysis of functional clusters and signalling pathways. MDA-CM treatment of wild type osteoblasts resulted in enrichment of two known pro-osteogenic signalling pathways, steroid biosynthesis and TGFβ signalling pathways, including promotion of expression of pro-osteogenic genes such as Bmp7 and Id1 and these effects were absent in MDA-CM treated PAR2 KO osteoblasts. MDA-CM treatment PAR2 dependently upregulated Grem1 expression, a marker of osteo-chondro progenitors with no adipocyte differentiation potential indicating the capacity of MDA-CM treated wild type osteoblasts to differentiate into osteoblast lineage, but not adipocyte lineage. Treatment with MDA-CM suppressed expression of the pro-adipogenic gene, Myc, in wild type osteoblasts, but not in PAR2 KO osteoblasts. In PAR2 KO osteoblasts, MDA-CM treatment suppressed the expression of the adipogenic inhibitor, Ctgf, an effect that is likely to contribute to the pro-adipogenic effect of MDA-CM in the absence of PAR2. Furthermore MDA-CM treatment PAR2 dependently enriched a functional cluster associated with angiogenesis that is known to promote prostate cancer bone metastasis. Within this functional cluster, MDA-CM mediated-PAR2 dependent upregulation was observed for Dhcr7,Id1, Epha2 and Ednra genes while Amot, Apoe, Arhgap22, Cspg4, Enpep, Hmox1, Kdr, Mmp14, Myo1e, Scg2, Sema3c, Sgpl1, and Vegfb genes were upregulated with MDA-CM treatment in both wild type and PAR2 KO osteoblasts. PAR2 independent osteoblastic upregulation of Mmp14, Amot, Apoe and Sema3c is of particular interest as these genes code for secretory or transmembrane proteins that regulate endothelial cell function to promote angiogenesis, thus contributing to the progression of prostate cancer bone metastasis. This thesis identifies a potential role for PAR2 in support of osteogenic bone metastases in prostate cancer using an in vitro model. Further studies are needed to confirm the role of PAR2 and downstream signalling pathways and individual genes identified in the current study in osteoblast responses, both in vitro and in vivo.
Institution: The University of Melbourne
Language: English
Topic: Bone Metabolism and Diseases
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2743528902
